Breast Oncology

Annals of Surgical Oncology

, Volume 16, Issue 2, pp 276-280

First online:

Comparative Analysis of Bone Marrow Micrometastases with Sentinel Lymph Node Status in Early-Stage Breast Cancer

  • Sukamal SahaAffiliated withSurgical Oncology, McLaren Regional Medical CenterSurgical Oncology, Advanced General and Oncological Surgical Associates
  • , Sarah AliAffiliated withInternal Medicine, McLaren Regional Medical Center
  • , Maher GhanemAffiliated withGeneral Surgery, Michigan State University
  • , Mehul SoniAffiliated withSurgical Oncology, McLaren Regional Medical Center
  • , David WieseAffiliated withPathology, McLaren Regional Medical Center
  • , Madan AroraAffiliated withMedical Oncology, Great Lakes Cancer CenterMedical Oncology, McLaren Regional Medical Center
  • , Trevor SinghAffiliated withMedical Oncology, Great Lakes Cancer CenterMedical Oncology, McLaren Regional Medical Center
  • , Douglas IddingsAffiliated withSurgical Oncology, Advanced General and Oncological Surgical AssociatesMedicine and Surgery, Michigan State University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Bone marrow micrometastases (BMM) and sentinel lymph node (SLN) status are both prognostic factors in breast cancer (BRCa) patients (pts). A definitive relationship between the two has not yet been proven and the data available is controversial. Thus, a retrospective study was conducted to determine the relationship of BM status and SLN status in pts with early BRCa (T1/T2). All female pts with early BRCa (T1/T2) operated upon by a single surgeon were included in the study. Prior to surgery, all pts underwent bone marrow aspiration from the posterior superior iliac spine bilaterally. Subsequently, pts underwent SLN biopsy and definitive primary breast surgery. BM samples were examined by using a Cytokeratin Detection Kit using CAM 5.2 monoclonal antibody. All pts with BMM underwent repeat BM analysis 6 months after completing all treatments. Data was collected for SLN, BM, estrogen receptor/progesterone receptor (ER/PR), and human epidermal growth factor receptor 2 (Her-2/neu) status and analyzed using chi-square (χ 2) analysis or Fischer’s exact test. A total of 270 consecutive pts with early BRCa were studied. SLN mapping was successful in all pts. SLN metastases (mets) were detected in 28.9% (78/270) pts. Of the 270 pts, 77.0% (208/270) had T1 disease. BMM were detected in 9.6% (26/270) pts, of whom 69.2% (18/26) were found to have BMM unilaterally. BMM were detected in 11.5% (9/78) pts with SLN mets versus 8.9% (17/192) in pts with node-negative disease (p = 0.65). Of the pts with T1 BRCa, BMM were observed in 9.1% (19/208) pts versus 11.3% (7/62) in pts with T2 BRCa (p = 0.6). In pts with ER/PR-negative (−ve) BRCa, BMM were found in 7.7% (2/26) pts versus 9.9% (24/242) in pts with ER/PR-positive (+ve) BRCa (p = 0.27). BMM were detected in 12.3% (9/73) pts with Her-2/neu +ve BRCa and in 8.6% (16/187) pts with Her-2/neu −ve BRCa (p = 0.11). After completion of adjuvant therapy all pts with BMM (n = 26) converted to BM negative status. We conclude that BM status did not correlate with SLN status and occurs independently of lymphatic metastasis possibly through a different mechanism. BMM occur in node-negative pts and may assist in identifying pts at high risk for disease recurrence. Obtaining bone marrow aspirate from two locations resulted in a significant increase in detection of micrometastases.